Quantum Genomics Overview

  • Founded
  • 2006

Founded
  • Status
  • Public

  • Employees
  • 9

Employees
  • Stock Symbol
  • ALQGC

Stock Symbol
  • Investments
  • 1

  • Share Price
  • $0.18

  • (As of Wednesday Closing)

Quantum Genomics General Information

Description

Quantum Genomics is a biopharmaceutical company engaged in developing new products for unmet needs in the field of cardiovascular diseases, high blood pressure, and heart failure. The company products include firibastat, QGC006, QGC011, and others.

Contact Information

Ownership Status
Publicly Held
Financing Status
Corporation
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Pharmaceuticals
Stock Exchange
PAR
Primary Office
  • 33 rue Marbeuf
  • 75008 Paris
  • France
+33 01 00 00 00 00

Quantum Genomics Timeline

2020202120222023
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Quantum Genomics Stock Performance

(As of Wednesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.18 $0.18 $0.12 - $4.70 $6.13M 34.5M 514K -$0.92

Quantum Genomics Financials Summary

In Thousands,
USD
TTM 30-Jun-2022 FY 2021 31-Dec-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019
EV 43,085 106,208 148,559 51,698
Revenue 1,010 137 1,372 0
EBITDA (27,350) (22,359) (15,795) (12,032)
Net Income (24,775) (19,574) (13,151) (10,163)
Total Assets 28,265 25,572 42,990 16,922
Total Debt 3,546 3,400 2 2
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Quantum Genomics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Quantum Genomics‘s full profile, request access.

Request a free trial

Quantum Genomics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Quantum Genomics is a biopharmaceutical company engaged in developing new products for unmet needs in the field of cardi
Biotechnology
Paris, France
9 As of 2022
00000
000000000 00000

000000

olore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco l
0000000000000
Burlington, MA
00 As of 0000
00000
0000000000 0 00000

000000

rit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur si
0000 000000000
Prague, Czech Republic
0000 As of 0000
00.000
000000000 00.000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Quantum Genomics Competitors (2)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Cardurion Pharma Venture Capital-Backed Burlington, MA 00 00000 0000000000 0 00000
0000000 Private Equity-Backed Prague, Czech Republic 0000 00.000 000000000 00.000
You’re viewing 2 of 2 competitors. Get the full list »

Quantum Genomics Patents

Quantum Genomics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2013336738-A1 Crystalline phase of (3s.3s') 4,4'-disulfanediylbis(3-aminobutane 1 -sulfonic acid) with l-lysine Active 22-Oct-2012 0000000000
AU-2013336738-B2 Crystalline phase of (3s.3s') 4,4'-disulfanediylbis(3-aminobutane 1 -sulfonic acid) with l-lysine Active 22-Oct-2012 0000000000
CA-2884914-A1 Crystalline phase of (3s.3s') 4,4'-disulfanediylbis(3-aminobutane 1 -sulfonic acid) with l-lysine Active 22-Oct-2012 0000000000
EP-2722327-A1 Crystalline phase of (3s,3s') 4,4'-disulfanediylbis (3-aminobutane 1-sulfonic acid) with l-lysine Inactive 22-Oct-2012 0000000000
EP-2909169-B1 Crystalline phase of (3s,3s') 4,4'-disulfanediylbis(3-aminobutane 1-sulfonic acid) with l-lysine Active 22-Oct-2012 C07C319/28
To view Quantum Genomics’s complete patent history, request access »

Quantum Genomics Executive Team (8)

Name Title Board Seat Contact Info
Jean-Philippe Milon Ph.D Chief Executive Officer & Board Member
Lionel Ségard President
Maurice Salama Board Member & Managing Director of International Multifinance
Benoit Gueugnon Administrative and Financial Director & Vice President, Finance
Stéphane Cohen Director of Global Operations
You’re viewing 5 of 8 executive team members. Get the full list »

Quantum Genomics Board Members (5)

Name Representing Role Since
000000 0000000000 Quantum Genomics Board Member 000 0000
000000000 0é0000 Self Board Member 000 0000
0000-00000000 0000 Quantum Genomics Chief Executive Officer & Board Member 000 0000
0000000 000000 Quantum Genomics Board Member & Managing Director of International Multifinance 000 0000
You’re viewing 4 of 5 board members. Get the full list »

Quantum Genomics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Quantum Genomics Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Quantum Genomics‘s full profile, request access.

Request a free trial

Quantum Genomics Acquisitions (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
0000000000 29-Oct-2007 0000000000 Consulting Services (B2B) 000000 0é
To view Quantum Genomics’s complete acquisitions history, request access »

Quantum Genomics ESG

Risk Overview

Risk Rating

Updated December, 21, 2022

28.14 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

00.0

Management

Management is related to actions taken to manage ESG issues

00.00

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

00 of 15,638

Rank

00.00

Percentile

Pharmaceuticals

Industry

00 of 1,008

Rank

00.00

Percentile

Biotechnology

Subindustry

00 of 465

Rank

00.00

Percentile

To view Quantum Genomics’s complete esg history, request access »

Quantum Genomics Exits (1)

Company Name Exit Date Exit Type Exit Size Status Buyers
0000000000 29-Oct-2007 000000000000000000 Completed
  • 0000000 00000000
To view Quantum Genomics’s complete exits history, request access »